None listed
Conditions
Brief summary
The purpose of this study is to determine which of two different intravenous anticoagulant strategies, currently in clinical use, is the safest and will have less associated bleeding complications. The study aims to test the hypothesis that use of bivalirudin has a lower rate of bleeding complications compared to heparin and glycoprotein IIb/IIIa inhibitor use.
Interventions
Treatment with bivalirudin (Angiomax). The recommended dosage of Angiomax for patients undergoing PCI is an intravenous (IV) bolus dose of 0.75 mg/kg followed by an IV infusion at a rate of 1.75 mg/kg/hour for the duration of the procedure, or for up to four hours post-PCI, as clinically indicated.
Sponsors
Professor John French
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with STEMI presenting within 12 hours of onset of symptoms 2. Administration of fibrinolytic therapy and failed reperfusion
Exclusion criteria
1. Contraindication to fibrinolytic therapy 2. Known hypersensitivity or contraindication to bivalirudin, heparin or glycoprotein inhibitors (GPI). 3. Severe renal impairment 4. Inability to give informed consent
Outcome results
None listed